Immuron Q3 Sales reach 150% of 1H Sales
April 06, 2023 06:00 ET
|
Immuron Limited
Highlights: Australian Q3 FY23 sales of A$577 k (201% of 1H sales)North American Q3 FY23 Travelan® sales of A$298 k (100% of 1H sales)Global Q3 YTD FY23 sales of A$1.46 M represent an increase of...
Immuron CEO, Steven Lydeamore to host an investor webinar
February 15, 2023 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
January 25, 2023 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
January 18, 2023 05:00 ET
|
Immuron Limited
Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place to enrol in 1302 healthy volunteers in...
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
January 17, 2023 07:10 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron Receives FDA Approval for Travelan IND Application
December 23, 2022 06:00 ET
|
Immuron Limited
Highlights: Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application IND to evaluate the efficacy of a single dose of Travelan to...
Immuron Submits IND Application To FDA for Travelan
December 05, 2022 06:00 ET
|
Immuron Limited
Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the...
Immuron completes strategic investment in leading gut health biotech Ateria Health
November 16, 2022 07:00 ET
|
Immuron Limited
Highlights: Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October...
Immuron CEO, Steven Lydeamore to present at AusBioInvest
October 26, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron strategic investment in leading gut health biotech Ateria Health
October 13, 2022 06:00 ET
|
Immuron Limited
Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of...